Abliva AB is a biopharmaceutical company dedicated to developing therapeutic solutions for individuals suffering from mitochondrial diseases. Focused on rare, life-threatening metabolic disorders, Abliva’s primary function is to bring innovative, effective treatments to patients with unmet medical needs. The company’s extensive research and development efforts aim to address mitochondrial dysfunctions that lead to progressive, debilitating syndromes. Abliva is engaged in the production of clinical-stage assets that target both primary and secondary mitochondrial disease, utilizing unique mechanisms to enhance energy production within cells. By operating within the pharmaceutical and biotech sectors, Abliva plays a critical role in driving advancements in personalized medicine and rare disease treatment strategies. Headquartered in Sweden, the company collaborates with academic institutions and healthcare professionals worldwide to accelerate the availability of novel medicinal products. Through its commitment to innovation and patient-centric solutions, Abliva AB serves as a pivotal contributor to the healthcare industry’s efforts in combating rare genetic diseases.